Tag: Algernon Pharmaceuticals Inc

December 10, 2019

Algernon Pharmaceuticals to Present at 12th Annual LD Micro Main Event Conference on Wednesday December 11, 2019

Algernon Pharmaceuticals Inc. is pleased to announce that it will present at the 12th Annual LD Micro Main Event Conference in...
December 9, 2019

Algernon Pharmaceuticals Selects NP-120 (Ifenprodil) for its Lead Phase 2 Trial for Idiopathic Pulmonary Fibrosis and Chronic Cough

Algernon Pharmaceuticals is pleased to announce that it plans to conduct its first phase 2 clinical trial of its repurposed...
December 5, 2019

Algernon Pharmaceuticals’ NP-120 (Ifenprodil) Outperforms Merck’s Phase 3 Drug MK-7264 (Gefapixant) in an Acute Cough Study by 110 Percent

Algernon Pharmaceuticals Inc. is pleased to announce that NP-120 (Ifenprodil) showed dramatic superiority over Gefapixant.
November 25, 2019

Algernon Pharmaceuticals Provides Update on its Planned Phase II Clinical Trial

Algernon Pharmaceuticals Inc. is pleased to provide an update to the market on its planned phase II clinical trial and...
November 1, 2019

Algernon Announces Closing of $2.07 Million Prospectus Offering of Units

Algernon Pharmaceuticals Inc. is pleased to announce the closing of its marketed short form prospectus offering pursuant.
July 29, 2019

Algernon Pharmaceuticals Announces Ifenprodil (NP-120) an NDMA Receptor Antagonist as its Lead Drug That Reduced Fibrosis in a Recent Idiopathic Pulmonary Fibrosis Study by 56%

Algernon Pharmaceuticals Inc. (CSE:AGN) is pleased to announce that NP-120, its lead compound in its idiopathic pulmonary fibrosis (IPF) research...